Young woman EPS rep
Young woman EPS rep

FOR US RESIDENTS ONLY

Patient Support

What is Eisai Patient Support?

Eisai Patient Support (EPS) provides information and resources to help patients get access to LENVIMA®. EPS offers assistance and information for patients taking LENVIMA, including:

red-icons/question

Understanding Insurance

red-icons/talking

Appeal information

red-icons/doc

Prior authorization
information

icon of a money

Financial assistance
program information

Financial Assistance

Eisai Patient Support can help eligible patients access programs to help pay for LENVIMA.

  • icon of a money

    LENVIMA Co-pay Program

    With the LENVIMA Co-pay Program, eligible commercially insured patients could pay as little as $0 out of
    pocket for each prescription. This program is not available to patients enrolled in state or federal healthcare
    programs, including Medicare, Medicaid, Medigap, VA, DoD, or TRICARE.

    To learn more about the program, including how to enroll, please talk to your pharmacist.

    For program eligibility, please see below.

    LENVIMA CO-PAY PROGRAM ELIGIBILITY TERMS & CONDITIONS

    Good toward the purchase of LENVIMA prescriptions. The LENVIMA Co-pay Program provides up to a maximum of $10,000 per year to
    assist with the out-of-pocket costs for LENVIMA. Depending on the insurance plan, a patient could have additional financial responsibility for
    any amounts over Eisai's maximum liability. No substitutions permitted. Not available to patients enrolled in state or federal healthcare
    programs, including Medicare, Medicaid, Medigap, VA, DoD, or TRICARE. Offer only available to patients with private, commercial insurance.
    Not valid for LENVIMA prescriptions reimbursed in full by any third-party payer. Save this information for reuse with each prescription. May
    not be combined with any other discount offer. The program is not valid for cash-paying customers. Federal law prohibits the selling,
    purchasing, trading, or counterfeiting of this card. Void outside of USA and where prohibited by law. Eisai Inc. reserves the right to rescind,
    revoke, or amend this offer at any time without notice. You must be 18 years or older to use this card for yourself. Patients and
    pharmacies are responsible for disclosing to insurance carriers the redemption and value of the program and complying with any other
    conditions imposed by insurance carriers, third-party payers, and applicable law on the redemption. The value of this program is not
    contingent on any prior or future purchases. This program offer may not be accepted at all pharmacies. This offer is not an insurance
    program. No membership fees.

  • icon of help up

    LENVIMA Patient Assistance Program

    The LENVIMA Patient Assistance Program provides LENVIMA at no cost to patients in need who meet
    program eligibility criteria.

    To apply for this program, you can download and complete this enrollment form or call Eisai Patient Support
    at 1-866-61-EISAI
    (1-866-613-4724)
    1-866-613-4724 Monday through Friday, 8 AM to 8 PM ET.

    Download the
     LENVIMA Eisai Patient Support Program Enrollment Form

    Descarga el
     formulario de inscripción en español

    For program eligibility, please see below.

    LENVIMA PATIENT ASSISTANCE PROGRAM ELIGIBILITY AND TERMS & CONDITIONS

    The LENVIMA Patient Assistance Program (''Program'') provides free drug for eligible patients who meet financial need and insurance
    coverage criteria. Patients must have a valid prescription for LENVIMA. Patient must be either uninsured or insured but without insurance
    coverage for LENVIMA (i.e., the insurer must have denied a first-level appeal of an initial coverage denial) or without enough coverage to pay
    for LENVIMA. Patient must have a household income equal to or less than 500 percent of the Federal Poverty Level. Patient must be a
    resident of the United States or Puerto Rico. Commercially insured patients and Federal health care program beneficiaries who qualify for
    the Program are enrolled for the entire calendar year. Uninsured patients who qualify for the Program are enrolled for a rolling 12-month
    period. All patients must re-enroll at the end of their respective Program approval period to ensure they continue to meet the Program's
    eligibility criteria. Eisai reserves the right to reassess eligibility for patients with commercial insurance during the enrollment period.
    The Program will ship LENVIMA directly to the patient's home address entered on the enrollment form. Product provided through the
    Program may not be sold, traded, bartered, transferred, or returned for credit. If the enrolled patient is no longer on theraphy or otherwise
    cannot use the free supply of LENVIMA, the provider agrees to promptly contact Eisai Patient Support to arrange for product return or destruction.

    No patient, pharmacy, payor, or other third-party may be billed for the free drug provided pursuant to the Program. Patients and providers
    must not submit any claim for reimbursement for product pursuant to this Program to any third-party payor, including Medicare, Medicaid, or
    any other federal or state health care program. Patient cannot apply the value of the free product received through this Program toward any
    insurance benefit out-of-pocket spending calculations such as Medicare Part D true out-of-pocket (TrOOP) Costs. The free LENVIMA
    provided under the Program is not contingent on any past or future purchases of any product, under the patient's insurance benefit or
    otherwise. Eligibility determinations are made without regard to patient's insurance provider (if any) or choice of physician.
    Patients are free to change physician at any time. The Program is not health insurance. Limitations may apply. Eisai reserves the right to
    rescind, revoke, or amend this Program at any time without notice. Additional terms and eligibility criteria apply. Contact Eisai Patient
    Support for additional information.

Resources

Access additional information about LENVIMA, including:

  • How LENVIMA works
  • Starting LENVIMA
  • What you should know about certain side effects

external link Visit LENVIMA.com

These independent patient organizations may provide assistance to patients, which may include options, such as educational tools, counseling and support groups.

*The organizations listed are independent from Eisai. Eisai does not influence or control the operations or eligibility criteria for these
independent programs. This information is provided for informational purposes only. For a comprehensive list of assistance offerings from
these independent organizations, please visit their websites.

Independent Patient Foundations

Certain independent third-party Foundations may offer assistance to eligible patients with healthcare expenses such as travel and lodging, or other expenses such as food, housing, or other state and local resources.

Explore foundations that may be able to help.

View Foundations alert icon alert icon

Eligibility criteria are determined by each independent third-party foundation. Eisai Patient Support does not determine eligibility and cannot guarantee foundations will offer assistance. Eisai has paid for the right to use this link. Eisai does not review the information on the website for accuracy or completeness and makes no claim about the accuracy of the information.

FAQs

  • WILL MY INSURANCE
    COVER LENVIMA?

    The best way to determine your coverage is to talk to your insurance carrier, your physician, or call EPS at 1-866-613-47241-866-613-4724 to speak to
    a Eisai Patient Support coordinator. Below, is some basic information about different types of insurance.

    TYPES OF INSURANCE

    Commercial insurance

    Commercial insurance is provided by nongovernment health plans such as health maintenance organizations (HMOs) and preferred provider
    organizations (PPOs). Many people purchase commercial health insurance through their employer’s health plan, or you can purchase an
    individual policy directly from commercial insurance providers. The exact coverage you receive depends on the specific policy that you
    purchase. Some insurance plans may provide coverage for LENVIMA. Commercially insured patients may be eligible for the LENVIMA Co-pay Program.

    Medicare

    The Medicare Part D drug benefit provides beneficiaries with coverage for outpatient prescription drugs. The Part D benefit is administered
    by private health plans, either stand-alone prescription drug plans (PDPs) or Medicare Advantage prescription drug (MA-PD) plans.
    Medicare established a standard benefit design for Part D with an annual deductible and either co-insurance or a co-pay. Part D plan
    sponsors may construct their own benefits, as long as their plan provides equal or better coverage than the standard.

    Medicaid

    Medicaid is a joint federal and state program that helps with medical costs for some people with limited income and resources. Each state
    sets its own coverage and eligibility rules for Medicaid programs. However, coverage and patient out-of-pocket costs vary from state to state.

  • WHAT IF MY INSURANCE
    COMPANY SAYS THEY
    WON'T PAY FOR LENVIMA?

    If you called your insurance company and were told that LENVIMA is not covered under your plan, or if you tried to fill a prescription for
    LENVIMA and learned that the drug is not covered, this is called a denial of coverage or denial of claim. You have the right to appeal this
    decision and request a detailed explanation in writing as to why you were denied. For assistance, call Eisai Patient Support at
    1-866-613-47241-866-613-4724 Monday through Friday, 8 AM to 8 PM ET.

  • WHERE CAN I GET LENVIMA ?

    There are two ways you can obtain LENVIMA:

    1. LENVIMA is available through Specialty Pharmacies that will mail the medication directly to you. If your medicine is being
      supplied by a Specialty Pharmacy, your healthcare team will tell you which Specialty Pharmacy will send it. Be sure to know the name of
      your Specialty Pharmacy and to respond promptly to their phone calls and communications.
    2. You can obtain LENVIMA directly from eligible physicians offices, clinics, or hospital pharmacies. For more information about how you will
      receive LENVIMA, please contact your healthcare team.
    red-icons/morter-pedastil

    Specialty Pharmacies

    AcariaHealth Logo
    acariahealth.
    envolvehealth.com

    Tel: 1-800-511-5144 1-800-511-5144

    Fax: 1-877-541-1503 1-877-541-1503

    Hours of Operation:

    Monday-Friday, 8am-8pm (ET)

    Saturday, 8am-3pm (ET)

    BioPlus Logo
    bioplusrx.com

    Tel: 1-888-292-0744 1-888-292-0744

    Fax: 1-800-269-5493 1-800-269-5493

    Hours of Operation:

    Monday-Friday, 8am-8pm (ET)

    krogerspecialtypharmacy.com

    Tel: 1-855-802-3230 1-855-802-3230

    Fax: 1-888-315-3270 1-888-315-3270

    Hours of Operation:

    Monday-Friday, 8am-8pm (ET)

    accredo.com

    Tel: 1-844-693-0156 1-844-693-0156

    Fax: 1-877-247-4847 1-877-247-4847

    Hours of Operation:

    Monday-Friday, 8am-9pm (ET)

    CVS Specialty Logo
    cvsspecialty.com

    Tel: 1-800-799-0692 1-800-799-0692

    Fax: 1-855-296-0210 1-855-296-0210

    Hours of Operation:

    Monday-Friday, 8am-6pm (ET)

    Onco360 Logo
    onco360.com

    Tel: 1-877-662-6633 1-877-662-6633

    Fax: 1-877-662-6355 1-877-662-6355

    Hours of Operation:

    Monday-Friday, 8am-8pm (ET)

    Saturday-Sunday, 9am-5:30pm (ET)

    amberpharmacy.com

    Tel: 1-888-370-1724 1-888-370-1724

    Fax: 1-855-370-0086 1-855-370-0086

    Hours of Operation:

    24 hours a day, 7 days a week

    Birdi Logo
    www.birdirx.com

    Tel: 1-877-437-9012 1-877-437-9012

    Fax: 1-877-309-0687 1-877-309-0687

    Hours of Operation:

    Monday-Friday, 8am-10pm (ET)

    Saturday, 8am-4:30pm (ET)

    specialty.optum.com

    Tel: 1-855-427-4682 1-855-427-4682

    Fax: 1-877-342-4596 1-877-342-4596

    Hours of Operation:

    Monday-Friday, 7am-9pm (CST)

    Saturday 8am-7pm (CST)

    Sunday: Closed

    Biologics Logo
    biologicsinc.com

    Tel: 1-800-850-4306 1-800-850-4306

    Fax: 1-800-823-4506 1-800-823-4506

    Hours of Operation:

    Monday-Friday, 8am-8pm (ET)

    CenterWell Logo
    www.humana.com/
    pharmacy/specialty-rx

    Tel: 1-800-486-2668 1-800-486-2668

    Fax: 1-800-405-7940 1-800-405-7940

    Hours of Operation:

    Monday-Friday, 8am-11pm (ET)

    Saturday, 8am-6:30pm (ET)

    AllianceRx Logo
    walgreens.com

    Tel: 1-866-202-4888 1-866-202-4888

    Fax: 1-888-440-6703 1-888-440-6703

    Hours of Operation:

    Monday-Friday, 8am-8pm (ET)

    Saturday, 8am-5pm (ET)

Eisai cannot guarantee payment of any claim. Coding, coverage, and reimbursement may vary significantly by payer, plan, patient, and setting
of care. Actual coverage and reimbursement decisions are made by individual payers following the receipt of claims. For additional
information, customers should consult with their payers for all relevant coding, reimbursement, and coverage requirements. It is the sole
responsibility of the provider to select the proper code and ensure the accuracy of all claims used in seeking reimbursement. All services
must be medically appropriate and properly supported in the patient's medical record.

What is LENVIMA?

LENVIMA is a prescription medicine that is used to treat certain kinds of cancer.

  • LENVIMA is used by itself to treat differentiated thyroid cancer (DTC), a type of thyroid cancer that can no longer be treated with radioactive iodine and is progressing
  • LENVIMA is used to treat adults with a type of kidney cancer called advanced renal cell carcinoma (RCC), along with the medicine everolimus after one course of treatment with another anti-cancer medicine (anti-angiogenic therapy)
  • LENVIMA is used by itself as the first treatment for a type of liver cancer called hepatocellular carcinoma (HCC) when it cannot be removed by surgery

The safety and efficacy of LENVIMA have not been established in children.

IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION

LENVIMA may cause serious side effects, including:

high blood pressure (hypertension): High blood pressure is a common side effect of LENVIMA and can be serious. Your blood pressure should be well controlled before you start taking LENVIMA. Your healthcare provider should check your blood pressure regularly during treatment with LENVIMA. If you develop blood pressure problems, your healthcare provider may prescribe medicine to treat your high blood pressure

heart problems: LENVIMA can cause serious heart problems that may lead to death. Call your healthcare provider right away if you get symptoms of heart problems, such as shortness of breath or swelling of your ankles

problem with blood clots in your blood vessels (arteries): Get emergency medical help right away if you get any of the following symptoms: severe chest pain or pressure; pain in your arms, back, neck, or jaw; shortness of breath; numbness or weakness on one side of your body; trouble talking; sudden severe headache; sudden vision changes

liver problems: LENVIMA may cause liver problems that may lead to liver failure and death. Your healthcare provider will check your liver function before and during treatment with LENVIMA. Tell your healthcare provider right away if you develop any of the following symptoms: your skin or the white part of your eyes turns yellow (jaundice); dark "tea-colored" urine; light-colored bowel movements (stools); feeling drowsy, confused or loss of consciousness

kidney problems: Kidney failure, which can lead to death, has happened with LENVIMA treatment. Your healthcare provider should do regular blood tests to check your kidneys

increased protein in your urine (proteinuria): Proteinuria is a common side effect of LENVIMA and can be serious. Your healthcare provider should check your urine for protein before and during your treatment with LENVIMA

diarrhea: Diarrhea is a common side effect of LENVIMA and can be serious. If you get diarrhea, ask your healthcare provider about what medicines you can take to treat your diarrhea. It is important to drink more water when you get diarrhea. Tell your healthcare provider or go to the emergency room, if you are unable to drink enough liquids and your diarrhea is not able to be controlled

an opening in the wall of your stomach or intestines (perforation) or an abnormal connection between two or more body parts (fistula): Get emergency medical help right away if you develop severe stomach (abdomen) pain

changes in the electrical activity of your heart called QT prolongation: QT prolongation can cause irregular heartbeats that can be life threatening. Your healthcare provider will do blood tests before and during your treatment with LENVIMA to check the levels of potassium, magnesium, and calcium in your blood, and may check the electrical activity of your heart with an electrocardiogram (ECG)

low levels of blood calcium (hypocalcemia): Your healthcare provider will check your blood calcium levels during treatment with LENVIMA and may tell you to take a calcium supplement if your calcium levels are low

a condition called Reversible Posterior Leukoencephalopathy Syndrome (RPLS): Call your healthcare provider right away if you get severe headache, seizures, weakness, confusion, or blindness or change in vision

bleeding: LENVIMA may cause serious bleeding problems that may lead to death. Tell your healthcare provider if you develop any signs or symptoms of bleeding during treatment with LENVIMA, including severe and persistent nose bleeds; vomiting blood; red or black (looks like tar) stools; blood in your urine; coughing up blood or blood clots; heavy or new onset vaginal bleeding

change in thyroid hormone levels: Your healthcare provider should check your thyroid hormone levels before starting and every month during treatment with LENVIMA

wound healing problems: Wound healing problems have happened in some people who take LENVIMA. Tell your healthcare provider if you plan to have any surgery before or during treatment with LENVIMA.

  • You should stop taking LENVIMA at least 1 week before planned surgery
  • Your healthcare provider should tell you when you may start taking LENVIMA again after surgery

severe jaw bone problems (osteonecrosis): Severe jaw bone problems have happened in some people who take LENVIMA. Certain risk factors such as taking a bisphosphonate medicine or the medicine denosumab, having dental disease, or an invasive dental procedure may increase your risk of getting jaw bone problems. Your healthcare provider should examine your mouth before you start and during treatment with LENVIMA. Tell your dentist that you are taking LENVIMA. It is important for you to practice good mouth care during treatment with LENVIMA. Tell your healthcare provider right away if you have any signs or symptoms of jaw bone problems during treatment with LENVIMA, including jaw pain, toothache, or sores on your gums and if you plan to have any dental procedures before or during treatment with LENVIMA.

  • You should stop taking LENVIMA at least 1 week before planned dental surgery or invasive dental procedures
  • Your healthcare provider should tell you when you may start taking LENVIMA again after dental procedures

The most common side effects of LENVIMA in people treated for thyroid cancer include tiredness, joint and muscle pain, decreased appetite, weight loss, nausea, mouth sores, headache, vomiting, rash, redness, itching, or peeling of your skin on your hands and feet, stomach (abdomen) pain, and hoarseness.

The most common side effects of LENVIMA in people treated for kidney cancer in combination with everolimus include tiredness, joint and muscle pain, decreased appetite, vomiting, nausea, mouth sores, swelling in your arms and legs, cough, stomach (abdomen) pain, trouble breathing, rash, weight loss, and bleeding.

The most common side effects of LENVIMA in people treated for liver cancer include tiredness, decreased appetite, joint and muscle pain, weight loss, stomach (abdomen) pain, rash, redness, itching, or peeling of your skin on your hands and feet, hoarseness, bleeding, decrease in thyroid hormone levels, and nausea.

LENVIMA may cause fertility problems in males and females and can harm your unborn baby.

Tell your healthcare provider if you are:

  • pregnant or plan to become pregnant. For females who are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with LENVIMA. Use an effective method of birth control (contraception) during treatment with LENVIMA and for 30 days after the last dose of LENVIMA
  • breastfeeding or plan to breastfeed. It is not known if LENVIMA passes into your breast milk. Do not breastfeed during treatment with LENVIMA and for 1 week after the last dose

Your healthcare provider may need to reduce your dose of LENVIMA, or delay or completely stop treatment if you have certain side effects.

These are not all the possible side effects of LENVIMA. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-10881-800-FDA-1088 or visit www.fda.gov/medwatch.

For more information about LENVIMA, please see full Prescribing Information.

What is LENVIMA?

LENVIMA is a prescription medicine that is used to treat certain kinds of cancer.

  • LENVIMA is used by itself to treat differentiated thyroid cancer (DTC), a type of thyroid cancer that can no longer be treated with radioactive iodine and is progressing
  • LENVIMA is used to treat adults with a type of kidney cancer called advanced renal cell carcinoma (RCC), along with the medicine everolimus after one course of treatment with another anti-cancer medicine (anti-angiogenic therapy)
  • LENVIMA is used by itself as the first treatment for a type of liver cancer called hepatocellular carcinoma (HCC) when it cannot be removed by surgery

The safety and efficacy of LENVIMA have not been established in children.

IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION

LENVIMA may cause serious side effects, including:

high blood pressure (hypertension): High blood pressure is a common side effect of LENVIMA and can be serious. Your blood pressure should be well controlled before you start taking LENVIMA. Your healthcare provider should check your blood pressure regularly during treatment with LENVIMA. If you develop blood pressure problems, your healthcare provider may prescribe medicine to treat your high blood pressure

heart problems: LENVIMA can cause serious heart problems that may lead to death. Call your healthcare provider right away if you get symptoms of heart problems, such as shortness of breath or swelling of your ankles

problem with blood clots in your blood vessels (arteries): Get emergency medical help right away if you get any of the following symptoms: severe chest pain or pressure; pain in your arms, back, neck, or jaw; shortness of breath; numbness or weakness on one side of your body; trouble talking; sudden severe headache; sudden vision changes

liver problems: LENVIMA may cause liver problems that may lead to liver failure and death. Your healthcare provider will check your liver function before and during treatment with LENVIMA. Tell your healthcare provider right away if you develop any of the following symptoms: your skin or the white part of your eyes turns yellow (jaundice); dark "tea-colored" urine; light-colored bowel movements (stools); feeling drowsy, confused or loss of consciousness

kidney problems: Kidney failure, which can lead to death, has happened with LENVIMA treatment. Your healthcare provider should do regular blood tests to check your kidneys

increased protein in your urine (proteinuria): Proteinuria is a common side effect of LENVIMA and can be serious. Your healthcare provider should check your urine for protein before and during your treatment with LENVIMA

diarrhea: Diarrhea is a common side effect of LENVIMA and can be serious. If you get diarrhea, ask your healthcare provider about what medicines you can take to treat your diarrhea. It is important to drink more water when you get diarrhea. Tell your healthcare provider or go to the emergency room, if you are unable to drink enough liquids and your diarrhea is not able to be controlled

an opening in the wall of your stomach or intestines (perforation) or an abnormal connection between two or more body parts (fistula): Get emergency medical help right away if you develop severe stomach (abdomen) pain

changes in the electrical activity of your heart called QT prolongation: QT prolongation can cause irregular heartbeats that can be life threatening. Your healthcare provider will do blood tests before and during your treatment with LENVIMA to check the levels of potassium, magnesium, and calcium in your blood, and may check the electrical activity of your heart with an electrocardiogram (ECG)

low levels of blood calcium (hypocalcemia): Your healthcare provider will check your blood calcium levels during treatment with LENVIMA and may tell you to take a calcium supplement if your calcium levels are low

a condition called Reversible Posterior Leukoencephalopathy Syndrome (RPLS): Call your healthcare provider right away if you get severe headache, seizures, weakness, confusion, or blindness or change in vision

bleeding: LENVIMA may cause serious bleeding problems that may lead to death. Tell your healthcare provider if you develop any signs or symptoms of bleeding during treatment with LENVIMA, including severe and persistent nose bleeds; vomiting blood; red or black (looks like tar) stools; blood in your urine; coughing up blood or blood clots; heavy or new onset vaginal bleeding

change in thyroid hormone levels: Your healthcare provider should check your thyroid hormone levels before starting and every month during treatment with LENVIMA

wound healing problems: Wound healing problems have happened in some people who take LENVIMA. Tell your healthcare provider if you plan to have any surgery before or during treatment with LENVIMA.

  • You should stop taking LENVIMA at least 1 week before planned surgery
  • Your healthcare provider should tell you when you may start taking LENVIMA again after surgery

severe jaw bone problems (osteonecrosis): Severe jaw bone problems have happened in some people who take LENVIMA. Certain risk factors such as taking a bisphosphonate medicine or the medicine denosumab, having dental disease, or an invasive dental procedure may increase your risk of getting jaw bone problems. Your healthcare provider should examine your mouth before you start and during treatment with LENVIMA. Tell your dentist that you are taking LENVIMA. It is important for you to practice good mouth care during treatment with LENVIMA. Tell your healthcare provider right away if you have any signs or symptoms of jaw bone problems during treatment with LENVIMA, including jaw pain, toothache, or sores on your gums and if you plan to have any dental procedures before or during treatment with LENVIMA.

  • You should stop taking LENVIMA at least 1 week before planned dental surgery or invasive dental procedures
  • Your healthcare provider should tell you when you may start taking LENVIMA again after dental procedures

The most common side effects of LENVIMA in people treated for thyroid cancer include tiredness, joint and muscle pain, decreased appetite, weight loss, nausea, mouth sores, headache, vomiting, rash, redness, itching, or peeling of your skin on your hands and feet, stomach (abdomen) pain, and hoarseness.

The most common side effects of LENVIMA in people treated for kidney cancer in combination with everolimus include tiredness, joint and muscle pain, decreased appetite, vomiting, nausea, mouth sores, swelling in your arms and legs, cough, stomach (abdomen) pain, trouble breathing, rash, weight loss, and bleeding.

The most common side effects of LENVIMA in people treated for liver cancer include tiredness, decreased appetite, joint and muscle pain, weight loss, stomach (abdomen) pain, rash, redness, itching, or peeling of your skin on your hands and feet, hoarseness, bleeding, decrease in thyroid hormone levels, and nausea.

LENVIMA may cause fertility problems in males and females and can harm your unborn baby.

Tell your healthcare provider if you are:

  • pregnant or plan to become pregnant. For females who are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with LENVIMA. Use an effective method of birth control (contraception) during treatment with LENVIMA and for 30 days after the last dose of LENVIMA
  • breastfeeding or plan to breastfeed. It is not known if LENVIMA passes into your breast milk. Do not breastfeed during treatment with LENVIMA and for 1 week after the last dose

Your healthcare provider may need to reduce your dose of LENVIMA, or delay or completely stop treatment if you have certain side effects.

These are not all the possible side effects of LENVIMA. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-10881-800-FDA-1088 or visit www.fda.gov/medwatch.

For more information about LENVIMA, please see full Prescribing Information.